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ABSTRACT
Angiotensin receptor blockers (ARBs) are the most
commonly used among blood pressure-lowering drugs
worldwide, despite the absence of sound evidence of
effectiveness in large and unbiased clinical trials. Meta-
analyses published in recent years and reviewed here
have not given support to this preference, suggesting
that ARBs may be ineffective in the prevention of all
cause mortality and major cardiovascular events
(particularly myocardial infarction). There is evidence
that ARB can be harmful for the kidney, particularly in
patients with diabetes and in the elderly. It may be
time to call for a moratorium on the preference for
ARB in the management of hypertension and in
patients with high cardiovascular risk.
Angiotensin receptor blockers (ARBs) are
the most commonly used blood pressure-
lowering drugs in the world. Nonetheless,
the results of large trials and meta-analyses
published in recent years and reviewed here
have not given support to this preference,
suggesting that they may be ineffective in the
prevention of all cause mortality and major
cardiovascular (CV) events (particularly myo-
cardial infarction). Moreover, there is evi-
dence that ARBs can increase the incidence
of acute kidney damage, particularly in
patients with diabetes and in the elderly. It
may be time to call for a moratorium on the
preference for ARB in the management of
hypertension and in patients with high car-
diovascular risk.
In a descriptive review, we identified that
ARBs were ineffective in preventing CV out-
comes in seven large placebo-controlled
trials in patients with high CV risk.1 In five of
these studies, the treatment with an ARB was
not superior to placebo in the prevention of
major CV events,2–6 and in two there was
higher CV mortality in patients treated with
an ARB instead of placebo.7 8 Moreover,
treatment with ARBs was associated with
worse renal outcomes in some trials, such as
increased incidence of microalbuminuria,
renal impairment and decreased glomerular
filtration rate.6 7 9–11 The presumptive effi-
cacy of ARB in the prevention of atrial fibril-
lation was not confirmed by four large
studies specifically designed to investigate
this effect.6 12–14
Four meta-analyses of these and other
trials converged in the identification of lack
of effectiveness of ARBs in the prevention of
major cardiovascular outcomes. The first
explored the efficacy of ARBs in the preven-
tion of myocardial infarction and other CV
outcomes.15 Patients had various criteria for
enrolment in the trials included in this
meta-analysis, such as hypertension, heart
failure, diabetes, stroke, atrial fibrillation and
others. In total, 37 randomised clinical trials
(RCTs), with 147 020 participants, were eval-
uated. When compared with placebo or
active treatment, ARBs were ineffective in the
prevention of myocardial infarction (relative
risk (RR) 0.99, 95% CI 0.92 to 1.07), death,
cardiovascular death or angina pectoris.
Compared with controls, ARBs were asso-
ciated with a reduction in the risk of stroke,
heart failure and new onset diabetes.
The second meta-analysis investigated the
efficacy of renin–angiotensin–aldosterone
system (RAAS) inhibitors over CV morbidity–
mortality trials.16 The trials should have at
least two-thirds of patients with hypertension.
The meta-analysis included 158 998 patients.
RAAS inhibition either with ACE inhibitors
(ACEi) or ARB was associated with a 5%
reduction in all-cause mortality (RR 0.95,
95% CI 0.91 to 1.00) and a 7% reduction in
CV mortality (RR 0.93, 95% CI 0.88 to 0.99).
When the trials were divided by the class of
RAAS inhibitor, the effect was identified to
be entirely due to ACEi (RR 0.90, 95% CI
0.84 to 0.97). Treatment with an ARB had no
effect in the prevention of all-cause mortality
(RR 0.99, 95% CI 0.94 to 1.04).
Another meta-analysis explored the effi-
cacy of ACEi and ARB in the prevention of
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cardiovascular disease (CVD) in patients with diabetes
and hypertension.17 Compared to placebo or other
active treatment, in 23 studies with 32 827 patients with
diabetes, ACEi significantly reduced the risk of all-cause
mortality by 13% (RR 0.87; 95% CI 0.78 to 0.98), the
incidence of CV deaths by 17% (0.83; 0.70 to 0.99),
major CV events by 14% (0.86; 0.77 to 0.95), including
myocardial infarction by 21% (0.79; 0.65 to 0.95) and
heart failure by 19% (0.81; 0.71 to 0.93). In contrast
with the effectiveness of ACEi, ARBs were ineffective in
reducing the risk for all-cause mortality (RR 0.94; 95%
CI, 0.82 to 1.08) in 13 studies controlled by placebo or
other active treatment, with a total of 23 867 patients
with diabetes. With the exception of a reduction in the
risk of heart failure (0.70; 0.59 to 0.82), ARBs were inef-
fective in the prevention of CV death (1.21; 0.81 to 1.80)
and major CV events (0.94; 0.85 to 1.01).
A fourth meta-analysis addressed the efficacy and
safety of ARB in elderly patients, in comparison with
active and placebo comparators.18 A total of 113 386 par-
ticipants were included. The incidence of all-cause mor-
tality and myocardial infarction were higher and
marginally significant in participants treated with ARB
(RR 1.03, 95% CI 1.00 to 1.06 and 1.04, 95% CI 0.96 to
1.12, respectively). Stroke and heart failure were less fre-
quent in patients treated with an ARB. Hypotension and
hyperkalemia were more common with ARB. A more
striking result, however, was the 48% increase in the risk
of acute kidney injury (95% CI from 24% to 97%). This
risk was similar to the risk described in individual
studies.1
The only study where an ARB was superior to the com-
parator was the LIFE trial.19 This study compared losar-
tan with atenolol, a β-blocker known to be ineffective in
the prevention of cardiovascular events in elderly
patients.20 Additionally, despite the fact that losartan sig-
nificantly reduced stroke compared to atenolol, there
were fewer patients with atrial fibrillation, tobacco use
and isolated systolic hypertension at baseline in the
losartan arm, giving an unfair advantage—specifically to
the stroke end point—that achieved significance.21 The
possibility that the LIFE trial is an outlier was demon-
strated in the meta-analysis of patients with diabetes.17
In the analysis with an active control group, the large
heterogeneity (I2=49%) was mainly derived from the
LIFE study. After excluding the LIFE study, heterogen-
eity and a trend for efficacy of ARB disappeared (I2=0%;
RR 0.96; 95% CI 0.77 to 1.20).
It is hard to explain how ARBs have reached such a
high level of preference in the treatment of hyperten-
sion worldwide, in the face of this overwhelming volume
of evidence demonstrating that they are probably inef-
fective in the prevention of all-cause mortality and many
manifestations of CV disease. The excessive valorisation
of the first studies performed with these drugs, which
investigated surrogate outcomes and were underpowered
to evaluate the effects over hard outcomes, may have ori-
ginated the misconception about their efficacy. The
basic research was oriented to the investigation of
mechanisms of action and effects of these drugs, and
the number of manuscripts describing favourable effects
of ARBs on experimental models is uncountable. The
massive commercial promotion of ARBs also had a key
role in the establishment of this preference. Many scien-
tists and opinion leaders worked towards helping
pharmaceutical companies to proclaim the superiority
of ARBs over traditional blood pressure-lowering drugs,
despite the absence of head-to-head comparisons with
diuretics in large RCTs. In addition, three RCTs pub-
lished in influential journals, which had showed very
favourable effects of ARB, were recently retracted
because of scientific fraud.22–24
The guidelines for the management of hypertension,
led mostly by the same opinion leaders, share the rec-
ommendation that ARBs should be the first options to
treat hypertension, particularly in patients with diabetes
and renal disease.25–27 These almost homogeneous
recommendations surely had a major role in the gener-
ation of the common belief about the superiority of
ARBs. And finally, doctors contributed to this prefer-
ence, since in the daily clinical practice they perceived
that these drugs were well tolerated (ie, ‘ACEi without
the cough’) and could not obviously perceive their inef-
ficacy to prevent CV outcomes. In the face of frequent
unsatisfactory blood pressure control with an ARB alone,
diuretics used to be added to the ARB to get better
blood pressure response.
The preference for ARBs is not supported by evidence
in the literature and may be denying patients the bene-
fits of being treated with proven blood pressure-lowering
agents. It may be time to call for a moratorium on the
preference for ARBs in the prevention of CVD in
patients with hypertension or diabetes.
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